Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
about
Adipose stem cell-based regenerative medicine for reversal of diabetic hyperglycemia.The use of animal models in diabetes research.A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodentsInduced pluripotent stem cells as a model for diabetes investigation.Discovery of dual-action membrane-anchored modulators of incretin receptorsPancreatic Beta Cell G-Protein Coupled Receptors and Second Messenger Interactions: A Systems Biology Computational AnalysisA novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice.Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice.Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease.Unravelling the stromal-nerve interactions in the human diabetic cornea.Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus.Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.Novel lipidized analogs of prolactin-releasing peptide have prolonged half-lives and exert anti-obesity effects after peripheral administration.A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents.RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.Lipidized prolactin-releasing peptide improved glucose tolerance in metabolic syndrome: Koletsky and spontaneously hypertensive rat study.Dogfish glucagon analogues counter hyperglycaemia and enhance both insulin secretion and action in diet-induced obese diabetic mice.
P2860
Q33759539-18CFCCA4-270C-4AFC-8CD0-A63C055D23A2Q34255921-2D2E955D-8888-4E42-8F4E-0C9E4913C70DQ34540961-D6313AF9-1AC4-4ED3-81C9-745710542596Q35123614-F8A6FF8B-1B4E-404D-81A5-A54DEFAA18ABQ35213989-463DE023-1D67-4770-9905-A52365F208E7Q36006492-F3ACBAEC-2BB8-4596-AB8F-D93265132A14Q37368747-2544D5FB-CE93-4770-8B23-41B46381F869Q38324750-BB8D0FE0-CB98-4610-A83E-0E67637829C0Q38583347-AF491F4D-03F3-4CE3-9BBC-2E651E36D555Q38615682-A9F20ECC-2111-413F-BE97-3BA20F11FA2DQ38668576-32761B52-ADE7-4AB6-B4A2-9447D50BC48EQ38830154-5EBB16DB-A223-46D9-8C03-E98D0281192FQ41221501-BED63B69-3C0A-45F1-81A0-3332E27CE7ADQ47207365-BDE4238D-DF65-4A1D-A6C2-E18D23E84B67Q47769365-5E2194A9-0798-4AB9-8936-C4896ECA0EFEQ50018586-3411BDBE-9476-4607-9E4D-D15331325AA9Q51282489-97263620-BCDB-40B7-B848-B330766459E7
P2860
Administration of an acylated GLP-1 and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Administration of an acylated ...... h Type 2 diabetes and obesity.
@en
type
label
Administration of an acylated ...... h Type 2 diabetes and obesity.
@en
prefLabel
Administration of an acylated ...... h Type 2 diabetes and obesity.
@en
P2860
P356
P1433
P1476
Administration of an acylated ...... th Type 2 diabetes and obesity
@en
P2093
Barry D Kerr
Patrick Harriott
P2860
P304
P356
10.1042/CS20110006
P407
P577
2011-08-01T00:00:00Z